drugset / Trial / NCT01894815

Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial

NCT01894815

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness and adverse effects. In this context, the investigators investigate a non-pharmacological treatment known as transcranial direct current stimulation (tDCS). To prove that tDCS is similarly effective than antidepressants would have a tremendous impact in clinical psychiatry, since tDCS is virtually absent of adverse effects. Its ease of use, portability and low price are also interesting characteristics for using in primary and secondary health care. Thus, our aim is to compare tDCS against a fully dosed, effective antidepressant. The study will be a non-inferiority, randomized, double-blinded, placebo-controlled, three-arm trial comparing active tDCS/placebo pill, sham tDCS/escitalopram 20mg/day and sham tDCS/placebo pill. Our primary aim is to show that tDCS is not inferior to escitalopram 20mg/day with a noninferiority margin of at least 50% of the escitalopram-placebo effect.

Timeline

Start
2013-10
Primary completion
2016-07
Completion
2016-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 20 mg Oral